Overview

• OHSU researchers have developed a nanoparticle technology that enhances high-intensity focused ultrasound (HIFU) cancer therapy by combining mechanical tumor ablation and targeted chemotherapy delivery.
• The nanoparticles amplify inertial cavitation, reducing ultrasound energy requirements by up to 100-fold while minimizing damage to surrounding healthy tissue.
• Functionalized with tumor-targeting peptides and a chemotherapeutic agent, the platform delivers a synergistic 'one-two punch' to cancer cells, improving treatment precision and efficacy.
• Preclinical trials in melanoma mouse models demonstrated complete tumor regression and sustained remission beyond 60 days with minimal side effects.
• The research team is now focusing on integrating the platform with immunotherapy and exploring broader biomedical applications to enhance cancer treatment outcomes.